Page 92 - 《中国药房》2025年16期

[ 3 ] ALMANGOUR T A，GHONEM L，ALJABRI A，et al. Dis，2021，73（9）：1664-1676.
Ceftazidime-avibactam versus colistin for the treatment of [14] NATH S，MOUSSAVI F，ABRAHAM D，et al. In vitro
infections due to carbapenem-resistant Enterobacterales：a and in vivo activity of single and dual antimicrobial agents
multicenter cohort study[J]. Infect Drug Resist，2022，15： against KPC-producing Klebsiella pneumoniae[J]. J Anti‐
211-221. microb Chemother，2018，73（2）：431-436.
[ 4 ] TORRES A，ZHONG N S，PACHL J，et al. Ceftazidime- [15] ZHENG G H，ZHANG J X，WANG B，et al. Ceftazidime-
avibactam versus meropenem in nosocomial pneumonia， avibactam in combination with in vitro non-susceptible an‐
including ventilator-associated pneumonia（REPROVE）：a timicrobials versus ceftazidime-avibactam in monotherapy
randomised，double-blind，phase 3 non-inferiority trial[J]. in critically ill patients with carbapenem-resistant Kleb-
Lancet Infect Dis，2018，18（3）：285-295. siella pneumoniae infection：a retrospective cohort study
[ 5 ] QIN X Y，TRAN B G，KIM M J，et al. A randomised， [J]. Infect Dis Ther，2021，10（3）：1699-1713.
double-blind，phase 3 study comparing the efficacy and [16] ZHONG H，ZHAO X Y，ZHANG Z L，et al. Evaluation of
safety of ceftazidime/avibactam plus metronidazole versus the efficacy and safety of ceftazidime/avibactam in the
meropenem for complicated intra-abdominal infections in treatment of Gram-negative bacterial infections：a syste-
hospitalised adults in Asia[J]. Int J Antimicrob Agents， matic review and meta-analysis[J]. Int J Antimicrob
2017，49（5）：579-588. Agents，2018，52（4）：443-450.
[ 6 ] LIN J，ZHANG L，ZHOU M L，et al. Combination [17] OJDANA D，GUTOWSKA A，SACHA P，et al. Activity
therapy of ceftazidime/avibactam for the treatment of pa‐ of ceftazidime-avibactam alone and in combination with
tients infected with carbapenem-resistant Klebsiella pneu‐ ertapenem，fosfomycin，and tigecycline against carbapenemase-
producing Klebsiella pneumoniae[J]. Microb Drug Resist，
moniae：a multicenter retrospective study[J]. Infect Dis
Ther，2023，12（8）：2165-2177. 2019，25（9）：1357-1364.
[ 7 ] FIORE M，ALFIERI A，DI FRANCO S，et al. Ceftazidime- [18] BULMAN Z P，CAO L S，CURRY B N，et al. Ceftazi‐
dime/avibactam alone or in combination with an amino‐
avibactam combination therapy compared to ceftazidime-
avibactam monotherapy for the treatment of severe infec‐ glycoside for treatment of carbapenem-resistant Entero‐
tions due to carbapenem-resistant pathogens：a systematic bacterales infections：a retrospective cohort study[J]. Int J
Antimicrob Agents，2024，64（5）：107321.
review and network meta-analysis[J]. Antibiotics（Basel），
2020，9（7）：388. [19] HU F P，ZHU D M，WANG F，et al. Current status and
[ 8 ] GAIBANI P，LEWIS R E，VOLPE S L，et al. In vitro trends of antibacterial resistance in China[J]. Clin Infect
Dis，2018，67（Suppl. 2）：S128-S134.
interaction of ceftazidime-avibactam in combination with [20] LU G P，TANG H，XIA Z X，et al. In vitro and in vivo anti‐
different antimicrobials against KPC-producing Klebsiella
microbial activities of ceftazidime/avibactam alone or in
pneumoniae clinical isolates[J]. Int J Infect Dis，2017，65：
combination with aztreonam against carbapenem-resistant
1-3. Enterobacterales[J]. Infect Drug Resist，2022，15：7107-
[ 9 ] KROEMER N，MARTENS M，DECOUSSER J W，et al. 7116.
Evaluation of in vitro pharmacodynamic drug interactions
[21] ACKLEY R，ROSHDY D，MEREDITH J，et al.
of ceftazidime/avibactam and fosfomycin in Escherichia Meropenem-vaborbactam versus ceftazidime-avibactam
coli[J]. J Antimicrob Chemother，2023，78（10）：2524- for treatment of carbapenem-resistant Enterobacteriaceae
2534.
infections[J]. Antimicrob Agents Chemother，2020，64
[10] ROMINA P E，LUCÍA A，LETICIA C，et al. In vitro effec‐ （5）：e02313-e02319.
tiveness of ceftazidime-avibactam in combination with [22] SHIELDS R K，HONG NGUYEN M，CHEN L，et al.
aztreonam on carbapenemase-producing Enterobacterales Pneumonia and renal replacement therapy are risk factors
[J]. J Glob Antimicrob Resist，2023，35：62-66. for ceftazidime-avibactam treatment failures and resis‐
[11] Clinical and Laboratory Standards Institute. Performance tance among patients with carbapenem-resistant Entero‐
standards for antimicrobial susceptibility testing[M]. M100 bacteriaceae infections[J]. Antimicrob Agents Chemother，
31st ed. Wayne，PA：Clinical and Laboratory Standards 2018，62（5）：e02497-e02517.
Institute，2021：41-55. [23] TAMMA P D，AITKEN S L，BONOMO R A，et al. Infec‐
[12] JORGENSEN S C J，TRINH T D，ZASOWSKI E J，et al. tious Diseases Society of America guidance on the treat‐
Real-world experience with ceftazidime-avibactam for ment of extended-spectrum β-lactamase producing Entero‐
multidrug-resistant Gram-negative bacterial infections[J]. bacterales（ESBL-E），carbapenem-resistant Enterobactera‐
Open Forum Infect Dis，2019，6（12）：ofz522. les（CRE），and Pseudomonas aeruginosa with difficult-to-
[13] TUMBARELLO M，RAFFAELLI F，GIANNELLA M，et treat resistance（DTR-P. aeruginosa）[J]. Clin Infect Dis，
al. Ceftazidime-avibactam use for Klebsiella pneumoniae 2021，72（7）：e169-e183.
carbapenemase-producing K. pneumoniae infections：a re- （收稿日期：2025-03-11 修回日期：2025-07-04）
trospective observational multicenter study[J]. Clin Infect （编辑：陈 宏）

· 2034 · China Pharmacy 2025 Vol. 36 No. 16 中国药房 2025年第36卷第16期